Arcutis Biotherapeutics, Inc. (ARQT) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds.
Is Arcutis Biotherapeutics, Inc. stock overvalued or undervalued in 2026?
Arcutis Biotherapeutics, Inc. (ARQT) trades at 154× earnings (P/E). No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Arcutis Biotherapeutics, Inc.
Market cap $4B · 52 weeks $20 – $33 (2 % below the high) · P/E 154× · 2027 est. P/E 24.4× · Dividend none · Next earnings November 4, 2026 · expected EPS $0.18 · Closing price, Oct 30 · accounts published Aug 5.
- Valuation: P/Sales 13.6× (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 7 of 8 (on track).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 1.9 %, fails.
- Market cap / Cash 18.5×, fails.
- Cash Runway 471 months, passes.
- Total Debt 0.1×, passes.
- Annual cash burn $0.04, info.
Against its peers (reference peers) — Arcutis Biotherapeutics, Inc.: P/E 154×; EV/EBITDA 94.7×; ROIC 9.9 %; $4.0B. Acadia Pharmaceuticals Inc. (P/E 9.3×; EV/EBITDA 27.9×; ROIC 6.2 %; $3.5B), PTC Therapeutics, Inc. (P/E —; EV/EBITDA 29.4×; ROIC 5.7 %; $5.0B), Telix Pharmaceuticals Limited (P/E 96.6×; EV/EBITDA 114×; ROIC -0.6 %; $3.1B).
Profitability
| Return on Equity | 15.05% |
| Return on Invested Capital | 9.95% |
| Return on Assets | 5.84% |
| Gross Margin | 91.14% |
| Operating Margin | 7.38% |
| Net Margin | 6.15% |
Financial Health
| Debt / Equity | 0.52 |
| Current Ratio | 2.92 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 6.98 |
Price Performance
| 1 month | +27.46% |
| 3 months | +23.20% |
| Year-to-date | +10.43% |
| 1 year | +26.71% |
| 3 years | +1214.34% |
| 5 years | +34.47% |
Related companies: VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of ARQT: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks